We have previously described a model for synthesizing protein- polysaccharide conjugate vaccines which stimulate enhanced antibody responses to both the polysaccharide and the protein components. In this proposal we describe novel approaches to refining this model to produce ~self-immunoadjuvanting~ vaccine constructs that will stimulate enhanced and persistent antibody responses to all of the components in a polysaccharide based vaccine. We have genetically engineered protein-cytokine fusions which will be conjugated to polysaccharides in order to enhance both the T cell dependent response as well as to focus cytokine help onto polysaccharide specific B cells. We have used IL2 and GM-CSF as the cytokine fusion partners, since we have shown that these cytokines can enhance Ig secretion to T cell independent type 2 (TI-type 2) antigens in vitro. As another approach to enhancing the T cell dependent limb of the response, we will construct CD40 ligand (CD40L)-protein fusions which will be conjugated to polysaccharides. We have shown that in vitro CD40L enhances Ig secretion to TI-type 2 antigens in both adult and neonatal cells. We will also genetically engineer a fusion of a cytokine with ~universal~ T cell epitope which will then be conjugated to polysaccharides. Finally, we will conjugate to polysaccharides a B cell stimulating peptide that we have shown induces enhanced B cell proliferation and Ig secretion only in the presence of multivalent mIg crosslinking stimulus. We will immunize normal, neonatal and CD4+ depleted mice via systemic and mucosal routes with these conjugates and measure the titer, persistence and isotype of antibody that is stimulated, as well as the protective efficacy of these antibodies using in vitro and in vivo models. The cellular mechanism underlying the enhancement of antibody responses will also be studied. These combined approaches will lay the groundwork for designing novel polysaccharide-based vaccines that stimulate high titer and persistent antibody in normal, neonatal and immune compromised hosts via systemic or mucosal routes.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Klein, David L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Henry M. Jackson Fdn for the Adv Mil/Med
United States
Zip Code
Shafer, D E; Schuman, R F; Lees, A (2001) Rapid and complete adsorption of unconjugated protein from protein-polysaccharide conjugate vaccines. Vaccine 19:1547-58
Shafer, D E; Toll, B; Schuman, R F et al. (2000) Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides Vaccine 18:1273-81
Vos, Q; Snapper, C M; Mond, J J (2000) T(h)1 versus T(h)2 cytokine profile determines the modulation of in vitro T cell-independent type 2 responses by IL-4. Int Immunol 12:1337-45
Goeckeritz, B E; Lees, A; Vos, Q et al. (2000) Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. Eur J Immunol 30:969-73
De Arruda Hinds, L B; Previato, L M; Previato, J O et al. (1999) Modulation of B-lymphocyte and NK cell activities by glycoinositolphospholipid purified from Trypanosoma cruzi. Infect Immun 67:6177-80
Wu, Z Q; Vos, Q; Shen, Y et al. (1999) In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. J Immunol 163:659-67
Goeckeritz, B E; Flora, M; Witherspoon, K et al. (1999) Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion. Int Immunol 11:1693-700
Wortham, C; Grinberg, L; Kaslow, D C et al. (1998) Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect Immun 66:1513-20
Halista, S M; Johnson-Robbins, L A; El-Mohandes, A E et al. (1998) Characterization of early activation events in cord blood B cells after stimulation with T cell-independent activators. Pediatr Res 43:496-503
Snapper, C M; Rosas, F R; Moorman, M A et al. (1997) Restoration of T cell-independent type 2 induction of Ig secretion by neonatal B cells in vitro. J Immunol 158:2731-5

Showing the most recent 10 out of 13 publications